PF-Atlas › Clinical Trials › NCT05537025

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

ARO-MMP7 Inhalation Solution · Phase 1

Registry ID
NCT05537025
Phase
Phase 1
Status
Completed
Drug / intervention
ARO-MMP7 Inhalation Solution
Sponsor
Arrowhead Pharmaceuticals
Start
2023-01-30
Enrollment
105
Locations
19

About this trial

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.

View NCT05537025 on ClinicalTrials.gov →

Explore related

All ARO-MMP7 Inhalation Solution trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05537025 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.